News
Gilteritinib maintenance reduces relapse in MRD+ AML
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
Despite not meeting its primary endpoint, a trial in mutated acute myeloid leukemia showed the benefit of gilteritinib maintenance in certain...
Warts completely resolved with treatment in only 24% of children undergoing active cancer treatment.
SCCs developed most frequently on the head/neck in organ transplant recipients and on the arms/hands in the general population.